{"groups":[{"description":"Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons.","id":"FG000","title":"Placebo"},{"description":"Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons. Participants who had any dose reductions due to adverse events (AEs) were not dose escalated.","id":"FG001","title":"Ixazomib Citrate"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"61"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}],"type":"Reason Not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"7"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"395"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"261"},{"groupId":"FG001","numSubjects":"395"}],"type":"Intent-to-Treat (ITT) Population"},{"achievements":[{"groupId":"FG000","numSubjects":"259"},{"groupId":"FG001","numSubjects":"394"}],"type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"256"},{"groupId":"FG001","numSubjects":"387"}],"type":"Per Protocol (PP) Population"},{"achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"322"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"73"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Participants with newly diagnosed multiple myeloma (NDMM) who underwent induction therapy according to regional standard of care (SoC), followed by high-dose melphalan (200 milligrams per meter square \\[mg/m\\^2\\]) and Autologous Stem Cell Transplant (ASCT) were enrolled in a 3:2 ratio to receive ixazomib citrate or placebo.","recruitmentDetails":"Participants enrolled at 167 sites globally to take part in this study from 16 July 2014 to 8 September 2023."}